Biogen Idec, Inc. (BIIB)
The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.
Recs
craigliles
(59.01)
Submitted: 11/17/2009 9:51:23 AM :
Start Price:
$46.10
BIIB Score:
+2.40
Gap to 70.00
Recs
Recs
SmallPimpin
(98.20)
Submitted: 10/21/2009 8:31:11 PM :
Start Price:
$46.38
BIIB Score:
-0.64
Mmm...pharmaceuticals...
Recs
kevinottofro
(98.71)
Submitted: 10/20/2009 12:00:16 PM :
Start Price:
$48.24
BIIB Score:
-4.01
Low relative PE, good star ranking, PEG & 09 PE still below normal - bottom fishing 10/19.
Recs
08PortfolioModel
(< 20)
Submitted: 10/7/2009 9:54:04 AM :
Start Price:
$44.85
BIIB Score:
+4.21
Current 48.93, Oct 6 09, Limit 46.11
Recs
erilis
(< 20)
Submitted: 6/17/2009 11:30:54 AM :
Start Price:
$52.19
BIIB Score:
-31.72
Doing fairly well in the crisis, if they continue with the same management and research stays up-to-date it will have a good future
Recs
onegoodguy521
(27.91)
Submitted: 5/28/2009 12:48:03 PM :
Start Price:
$50.85
BIIB Score:
-32.14
Three to four companies looking to buy BIIB for new drug pipeline.
Recs
ELPisthebest
(96.40)
Submitted: 3/6/2009 7:15:56 PM :
Start Price:
$43.53
BIIB Score:
+57.75
This stock will be one of the few companies who will benefit from Obama's Universal Healthcare
Recs
zzlangerhans
(99.52)
Submitted: 2/27/2009 1:12:50 AM :
Start Price:
$48.80
BIIB Score:
-50.52
Just as Obama enthusiasm for stem cell stocks is senseless, Obama pessimism for pharmaceuticals is overblown. I don't believe his policies will fundamentally change the business model or profitability of mid-to-large cap biotechs, and I see this as another opportunity to green thumb some quality companies at depressed prices.
Recs
buckywildcat
(< 20)
Submitted: 1/11/2009 10:41:34 PM :
Start Price:
$46.80
BIIB Score:
+26.20
Numerous competitors entering the MS therapeutic field with several potential oral drugs on the horizon. Significant loss of market share will erode BIIB revenues by 2010.
Recs
PrestigeWW
(90.22)
Submitted: 12/2/2008 3:29:37 AM :
Start Price:
$39.61
BIIB Score:
-17.14
biotech will outperform in the long run
Recs
OtterPater
(< 20)
Submitted: 11/13/2008 4:39:42 PM :
Start Price:
$46.38
BIIB Score:
-25.48
Not a one horse stable - it has Tysabri and more.
Recs
Gumfactor
(86.48)
Submitted: 11/8/2008 5:08:25 PM :
Start Price:
$47.21
BIIB Score:
-19.57
We all know that biotech is good in a recession. And so I'm probably going to stock up on a few of them over the coming weeks.
But take a look at Biogen, in particular, for several reasons:
A) It's #7 of all biotech companies, as ranked by revenue.
B) It's stock price has dropped 40% in the last year.
C) It was just upgraded by Deusche Bank on Tuesday.
D) A 10 year chart of the company might just make your mouth water. Or make you worry, depending on your predilection. Here's the scoop:
Over 10 years, there are remarkably consistent tops and bottoms that have created a nearly perfectly linear stock price increase over that period. Even people not akin to technical analysis can't possibly ignore a 10-year pattern like this. About 6 months ago, the stock hit the bottom of this trend cycle...and broke under this 10 year resistance point. Since then, the stock has dropped approx. 25%, and has, as I said before, recently been upgraded. Which suggests to me, for reasons A, B and C listed above, that the stock is likely to come back *at least* back to testing that 10-year resistance point. That, alone, would mean an increase from $45 to approx. $55-60. But given the remarkably consistent performance of this company over the past decade, and the fact that there is really no reason to feel worse about it now than previously, I think the chances that it gets back on its 10-year trend is pretty good. If it does this, the trend suggests we should see $80-$90 within about 12-18 months.
There you have it. That's my take.
Recs
FlawedGenius
(88.91)
Submitted: 10/22/2008 3:10:21 PM :
Start Price:
$41.16
BIIB Score:
-11.23
Defensive growth
Recs
RNZ100
(81.08)
Submitted: 10/8/2008 8:24:29 PM :
Start Price:
$47.14
BIIB Score:
-14.05
Oversold (but then again, what isn't?!)
Recs
dcamsterdam
(89.22)
Submitted: 10/1/2008 2:08:23 PM :
Start Price:
$48.55
BIIB Score:
-1.09
Democrats will spend more on health care, I like current price
Recs
mjan706
(< 20)
Submitted: 9/22/2008 1:39:33 AM :
Start Price:
$50.13
BIIB Score:
+2.94
An Icahn portfolio stock.
Recs
schmuuz
(< 20)
Submitted: 8/26/2008 11:04:18 AM :
Start Price:
$54.12
BIIB Score:
+2.44
I think the only reason of the last fell was the last PML..... I say all treatments have problems and unexpected events. I think with the number of patients you can see that for the most patients the treatments is as safety as possible and helps. As I would have MS I am sure that I would go for Tysabri!!!!
Recs
SuperStocker1
(55.30)
Submitted: 8/14/2008 9:25:06 PM :
Start Price:
$54.86
BIIB Score:
-1.96
Recovery breakout upwards
Recs
addaam78
(91.23)
Submitted: 8/8/2008 4:19:29 PM :
Start Price:
$50.35
BIIB Score:
+5.48
Great, innovative company with earnings and revenue growth. It markets 4 drugs at the moment and has lost some 20% in a few days due to the Tysabri scare.
It is a possible takeover target and if the drug is not pulled out of the market it still does not represent a large portion of its revenue.
The company does not look cheap at 21 P/E, but if the Tysabri drug is not pulled out of the market, and looking at the past innovative drugs they have made... I think the company's future can be bright.
At current levels is not cheap, but it is reasonably valued and due to market over-pessimism it could go lower. So I will scale in at current levels.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 81 1 2 3 4 5 Next »